PIK3CG and breast cancer: The precise mechanism of SGK3 induction remains unknown; however, SGK3 has been reported to be an oestrogen transcriptional target in ER+ breast cancer suggesting that low levels changes in oestrogen signalling may be sufficient to drive downstream mTOR activation, limiting the use of single agent PI3K pathway inhibitors (see below) [168].